- Home
- SKYE vs OBAI Comparison
SKYE vs OBAI Comparison
Compare SKYE & OBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYE | OBAI |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 25.2M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | SKYE | OBAI |
|---|---|---|
| Price | $0.83 | $0.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 198.7K | ★ 1.4M |
| Earning Date | 05-08-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.44 |
| 52 Week High | $5.75 | $19.95 |
Technical Indicators
Market Signals| Indicator | SKYE | OBAI |
|---|---|---|
| Relative Strength Index (RSI) | 52.61 | 21.75 |
| Support Level | $0.68 | $0.44 |
| Resistance Level | $1.15 | $0.66 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 30.98 | 16.96 |
Price Performance
Historical ComparisonAbout SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About OBAI TG-17 Inc. Common Stock
Our Bond Inc is a personal security service through its AI-powered Preventive Personal Security platform. It is trusted by corporations, cities, and universities, and has already supported more than 1.4 million security service requests, including over 10,000 emergencies and life-saving interventions.